DAVID CUNNINGHAM, Royal Marsden Hospital, London
The oral agent capeticabine is just as effective as fluorouracil for treating patients whose metastatic colorectal cancer has relapsed. This is the finding of a study in which either agent was combined with oxaliplatin. David Cunningham told Peter Goodwin about his group’s findings reported at the ECCO conference.
Cetuximab With Irinotecan Slows Progression For Patients With Colorectal Cancer: The EPIC Trial
WERNER SCHEITHAUER, Medical University of Vienna
COMMENT: DAVID CUNNINGHAM, Royal Marsden Hospital, London
For patients with metastatic colorectal cancer who have failed prior oxaliplatin therapy, cetuximab plus irinotecan could be the best treatment. This is according to a study that randomly assigned patients to irinotecan with or without cetuximab. Sarah Maxwell spoke to EPIC Trial author Werner Scheithauer while David Cunningham provided comment.
Sunitinib and Sorafenib: Expanded Access Data in Renal Cell Cancer
JANICE DUTCHER, Our Lady of Mercy Medical Center, Bronx, NY
Encouraging clinical benefits have emerged among patients with renal cell cancer treated with sunitinib and sorafenib who do not fulfill the usual criteria for clinical trials with these tyrosine kinase inhibitors. Janice Dutcher told Peter Godwin about findings from an “expanded access” program.
Pazopanib and Perifosine: New, Active Targeted Therapies in Renal Cancer
ROBERT FIGLIN, City of Hope Comprehensive Cancer Center, Los Angeles
Pazopanib and perifosine are two new agents that have performed well in phase II studies of renal cell carcinoma. Derek Thorne asked Robert Figlin about the data on these drugs, and about what doctors should make of the increasing number of targeted therapies emerging for kidney cancer.
IRX-II: A Novel Agent for Immune Modulation Therapy for Head and Neck Cancer
GREGORY WOLF, University of Michigan, Ann Arbor
An immune approach to treating cancer of the head and neck looks promising. Gregory Wolf told conference delegates at the Chemotherapy Foundation Symposium that clinical responses to a novel agent have been reported from Mexico, and that his group is now testing the same agent (IRX-II) in pilot studies. He talked with Peter Goodwin.